A Systematic Review and Meta-Analysis of Randomised Controlled Trials Assessing Clinical and Haemodynamic Outcomes of Ivabradine in Heart Failure With Reduced Ejection Fraction Patients.
Yoga WaranugrahaArdian RizalCholid Tri TjahjonoIrene Yasmina ViladoNathanael Ibot DavidFikri AbudanDwi Ayu SetyaningrumPublished in: Heart, lung & circulation (2024)
Ivabradine can reduce the risk of HF mortality and HF hospitalisation in HFrEF patients. Ivabradine also effectively reduces resting heart rate and improves LVEF. However, ivabradine is associated with a greater risk of symptomatic and asymptomatic bradycardia.
Keyphrases
- heart rate
- end stage renal disease
- heart rate variability
- heart failure
- blood pressure
- chronic kidney disease
- newly diagnosed
- ejection fraction
- peritoneal dialysis
- prognostic factors
- cardiovascular disease
- patient reported outcomes
- metabolic syndrome
- atrial fibrillation
- skeletal muscle
- cardiovascular events
- glycemic control